Trials / Completed
CompletedNCT02192970
Bevacizumab Against Recurrent Retinal Detachment
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 101 (actual)
- Sponsor
- University of Wisconsin, Madison · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The investigators hypothesize that bevacizumab instilled into the vitreous after primary retinal detachment surgery will reduce the formation of proliferative vitreoretinopathy and subsequent retinal re-detachment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bevacizumab |
Timeline
- Start date
- 2015-01-21
- Primary completion
- 2019-11-11
- Completion
- 2019-11-11
- First posted
- 2014-07-17
- Last updated
- 2021-03-26
- Results posted
- 2021-03-26
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02192970. Inclusion in this directory is not an endorsement.